New report on CEL-SCI's H1N1 flu drug candidate

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Sep 24 2009

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published a new report about CEL-SCI Corporation's (NYSE Amex: CVM) new H1N1 flu drug candidate.

Hype versus substance. Perception versus reality. During the past week, there has been much debate regarding the work being done by CEL-SCI in the pandemic influenza space, but previously published data may help shed new light on the L.E.A.P.S platform which is being used to develop the treatment.

Are there applications for CEL-SCI's work beyond the scope and urgency of the current pandemic that may open up other lucrative markets?

The new article can be read in their entirety at BioMedReports.Com:

Source:

http://biomedreports.com/component/content/article/56-top-leading-news/10621-intriguing-revelations-deciphering-cel-scis-h1n1-flu-play.html

Posted in: Pharmaceutical News

Tags: , , ,

Comments (0)

Suggested Reading

Avian flu's leap to humans: Understanding risks and prevention strategies
Study reveals BCG vaccine's unexpected role in fighting influenza
Study shows potential for universal flu vaccine with broad antibody response
Researchers develop promising recombinant flu vaccine using nanoliposome technology
U.S. flu vaccines expected to shift from quadrivalent to trivalent, researcher says
Promising influenza drug candidate shows activity against resistant variants
Researchers create novel drug that can prevent flu-induced lung injury
Metabolic health determines effectiveness of influenza vaccination

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
October births linked to higher flu vaccination and lower diagnosis rates